Regenxbio Inc- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Regenxbio Inc 公司

REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.

Regenxbio Inc简介



公司代码RGNX

公司名称Regenxbio Inc

上市日期Sep 17, 2015

CEOSimpson (Curran M)

员工数量353

证券类型Ordinary Share

年结日Sep 17

公司地址9804 Medical Center Drive

城市ROCKVILLE

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编20850

电话12405528181

网址https://regenxbio.com/

公司代码RGNX

上市日期Sep 17, 2015

CEOSimpson (Curran M)

Regenxbio Inc公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Mitchell Chan

Chief Financial Officer, Executive Vice President, Principal Accounting Officer

127.72K

+57.74%

Mr. Craig Malzahn

Executive Vice President - Product Development, Chief Technology Officer

82.19K

+78.61%

Dr. Olivier Danos, Ph.D.

Executive Vice President, Chief Scientific Officer

58.37K

-123.06%

Mr. Curran M. Simpson

President, Chief Executive Officer, Director

45.81K

-165.45%

Ms. Jennifer L. Zachary

Independent Director

22.06K

+9.10%

Mr. Daniel Tasse

Lead Independent Director

19.05K

--

Mr. George V. Migausky

Independent Director

19.05K

--

Mr. Kenneth T. (Ken) Mills

Chairman of the Board

--

Dr. A. N. (Jerry) Karabelas, Ph.D.

Independent Director

--

Mr. Allan M. Fox, J.D.

Director

--

名称

名称/职务

职务

持股

持股变动

Mr. Mitchell Chan

Chief Financial Officer, Executive Vice President, Principal Accounting Officer

127.72K

+57.74%

Mr. Craig Malzahn

Executive Vice President - Product Development, Chief Technology Officer

82.19K

+78.61%

Dr. Olivier Danos, Ph.D.

Executive Vice President, Chief Scientific Officer

58.37K

-123.06%

Mr. Curran M. Simpson

President, Chief Executive Officer, Director

45.81K

-165.45%

Ms. Jennifer L. Zachary

Independent Director

22.06K

+9.10%

Mr. Daniel Tasse

Lead Independent Director

19.05K

--

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 5月13日周三

持股股东

股东类型

持股股东

占比

Redmile Group, LLC

8.46%

BlackRock Institutional Trust Company, N.A.

7.73%

Fox (Allan Mark)

5.62%

State Street Investment Management (US)

5.29%

JP Morgan Asset Management

4.91%

其他

67.98%

持股股东

占比

Redmile Group, LLC

8.46%

BlackRock Institutional Trust Company, N.A.

7.73%

Fox (Allan Mark)

5.62%

State Street Investment Management (US)

5.29%

JP Morgan Asset Management

4.91%

其他

67.98%

股东类型

持股股东

占比

Investment Advisor

31.72%

Investment Advisor/Hedge Fund

31.68%

Hedge Fund

8.28%

Research Firm

8.11%

Individual Investor

7.56%

Private Equity

0.97%

Corporation

0.53%

Bank and Trust

0.37%

Family Office

0.36%

其他

10.43%

机构持股



更新时间: 4月1日周三

报告期

机构数

持股数

持股占比

持股变动

2026Q1

410

45.28M

87.72%

-3.48M

2025Q4

409

42.94M

84.82%

-6.24M

2025Q3

403

44.05M

87.32%

-5.71M

2025Q2

421

48.19M

95.62%

-3.63M

2025Q1

446

48.46M

96.35%

-3.90M

2024Q4

444

48.16M

97.22%

-4.82M

2024Q3

444

49.64M

100.43%

-4.45M

2024Q2

437

49.30M

99.98%

-3.20M

2024Q1

451

48.23M

99.21%

+414.63K

2023Q4

436

43.62M

98.84%

-7.14M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Redmile Group, LLC

4.37M

8.46%

-324.58K

-6.92%

Dec 31, 2025

BlackRock Institutional Trust Company, N.A.

3.99M

7.73%

-165.79K

-3.99%

Dec 31, 2025

Fox (Allan Mark)

2.90M

5.62%

+7.77K

+0.27%

May 30, 2025

State Street Investment Management (US)

2.29M

4.43%

+301.86K

+15.21%

Dec 31, 2025

JP Morgan Asset Management

2.53M

4.91%

-76.70K

-2.94%

Dec 31, 2025

Morgan Stanley & Co. LLC

1.74M

3.38%

+296.91K

+20.55%

Dec 31, 2025

Goldman Sachs & Company, Inc.

1.52M

2.95%

-96.48K

-5.95%

Dec 31, 2025

AQR Capital Management, LLC

1.36M

2.64%

+72.31K

+5.61%

Dec 31, 2025

Integral Health Asset Management, LLC

1.20M

2.33%

+100.00K

+9.09%

Dec 31, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

WisdomTree BioRevolution Fund

2.25%

iShares Neuroscience and Healthcare ETF

1.02%

Virtus LifeSci Biotech Clinical Trials ETF

0.85%

Global X Genomics & Biotechnology ETF

0.65%

JPMorgan Fundamental Data Science Small Core ETF

0.45%

ALPS Medical Breakthroughs ETF

0.27%

State Street SPDR S&P Biotech ETF

0.24%

Direxion Daily S&P Biotech Bull 3X Shares

0.13%

Fidelity Enhanced Small Cap ETF

0.12%

ProShares Ultra Nasdaq Biotechnology

0.08%

WisdomTree BioRevolution Fund

占比2.25%

iShares Neuroscience and Healthcare ETF

占比1.02%

Virtus LifeSci Biotech Clinical Trials ETF

占比0.85%

Global X Genomics & Biotechnology ETF

占比0.65%

JPMorgan Fundamental Data Science Small Core ETF

占比0.45%

ALPS Medical Breakthroughs ETF

占比0.27%

State Street SPDR S&P Biotech ETF

占比0.24%

Direxion Daily S&P Biotech Bull 3X Shares

占比0.13%

Fidelity Enhanced Small Cap ETF

占比0.12%

ProShares Ultra Nasdaq Biotechnology

占比0.08%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

除权除息日

类型

比率

暂无数据

公告日期

除权除息日

类型

比率

暂无数据